Pretax income is the income that a company earns before paying income taxes. Tenax Therapeutics's pretax income for the
three
months ended in Mar. 2024 was $-3.80 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.10 Mil.
Tenax Therapeutics's pretax margin was %.
During the past 13 years, Tenax Therapeutics's highest Pretax Margin was -6761.94%. The lowest was -28738.78%. And the median was -17750.36%.
Tenax Therapeutics Pre-Tax Income Historical Data
The historical data trend for Tenax Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tenax Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Tenax Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's Pre-Tax Income falls into.
Tenax Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Tenax Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (NAS:TENX) Pre-Tax Income Explanation
Tenax Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 13 years, Tenax Therapeutics's highest Pretax Margin was -6761.94%. The lowest was -28738.78%. And the median was -17750.36%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Tenax Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Tenax Therapeutics (Tenax Therapeutics) Business Description
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TENX has been successfully added to your 